C61 Malignant neoplasm of prostate.
The patient was diagnosed with stage 4 poorly differentiated prostate adenocarcinoma G3 (Gleason 5+5=10).
In May 2019, multiple metastases were found in bones (axial skeleton).
Hormone therapy (Goserelin), chemotherapy (Docetaxel), zoledronic acid for bone metastases.
Patients diagnosed at stage 4, five-year survival rate is approximately 29%.
Autologous DCV. Immunotherapy was commenced in March-August 2020.
The patient survived 4 years after diagnosis.